IP Library › Granted Patent US 12,599,432
Granted Patent B2
US 12,599,432 · App. 17/502,640 · Granted Apr 14, 2026

Devices, systems and methods for the treatment of abnormal tissue

Inventors: Seth S. Gleiman (Guilford, CT); Nicholas S. Mercer (San Francisco, CA); Timothy J. O'Brien (Santa Clara, CA); Jonathan R. Waldstreicher (West Orange, NJ); Kevin J. Taylor (San Mateo, CA); Luis L. Mangual Arbelo (Sunnyvale, CA); Robert E. Neal (Redwood City, CA); William Sanford Krimsky (Forest Hill, MD); Quim Castellvi (Barcelona, ES)
Assignee: Galvanize Therapeutics, Inc.
A61B18/1492A61B18/02A61B18/16A61B2018/00267A61B2018/00327A61B2018/00351A61B2018/00404A61B2018/0044A61B2018/00488A61B2018/00494A61B2018/005A61B2018/00511A61B2018/00517A61B2018/00559A61B2018/00577A61B2018/00613A61B2018/1253
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,599,432
App. No.
17/502,640
Filed
Oct 15, 2021
Granted
Apr 14, 2026
Kind
B2
Art Unit
3794
USPC
606/41
Abstract

Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.

Claims (32)

1 . A method of treating target tissue cells within a body of a patient having a luminal structure, the method comprising:

treating a first portion of the target tissue cells, wherein the first portion of the target tissue cells reside outside of the luminal structure, and wherein the treating of the first portion is in a manner that would damage an extracellular matrix of the luminal structure if applied thereto;

advancing a distal end of an instrument into the luminal structure of the body, wherein the instrument includes an energy delivery body disposed along its distal end; and

delivering pulsed electric field energy from the energy delivery body toward the target tissue cells, wherein the pulsed electric field energy treats at least some of the first portion of the target tissue cells and treats a second portion of the target tissue cells, wherein the second portion of the target tissue cells reside at least partially within a wall of the luminal structure while maintaining of the luminal structure.

2 . A method as in claim 1 , wherein the first portion of the target tissue cells reside up to 20 cm away from an exterior of the luminal structure.

3 . A method as in claim 1 , wherein treats comprises destroys.

4 . A method as in claim 1 , wherein treats comprises increases the vulnerability of the target tissue cells to premature death.

5 . A method as in claim 1 , wherein treats the second portion comprises increases the uptake of agents by the target tissue cells of the second portion.

6 . A method as in claim 1 , further comprising expanding the energy delivery body within the luminal structure.

7 . A method as in claim 6 , wherein the energy delivery body comprises a basket-shaped electrode configured to be expanded so as to reside near or against an interior surface of the luminal structure, wherein the basket-shaped electrode delivers the pulsed electric field energy.

8 . A method as in claim 1 , further comprising penetrating a wall of the luminal structure with the energy delivery body.

9 . A method as in claim 8 , wherein at least a portion of the energy delivery body comprises a probe tip, and wherein penetrating comprises advancing the probe tip from the distal end of the instrument beyond the wall of the luminal structure.

10 . A method as in claim 9 , wherein at least a portion of the energy delivery body comprises a plurality of probe elements, and wherein penetrating comprises advancing the plurality of probe elements beyond the wall of the luminal structure.

11 . A method as in claim 10 , wherein advancing the plurality of probe elements comprises individually advancing at least one of the plurality of probe elements in relation to another of the plurality of probe elements.

12 . A method as in claim 10 , wherein delivering pulsed electric field energy comprises delivering different pulsed electric field energy from at least one of the plurality of the probe elements in relation to another of the plurality of probe elements.

13 . A method as in claim 10 , wherein delivering pulsed electric field energy comprises:

delivering a first pulsed electric field energy from a first probe element of plurality of probe elements so as to create a first ablation zone and

delivering a second pulsed electric field energy from a second probe element of the plurality of probe elements so as to create a second ablation zone,

wherein the first ablation zone and the second ablation zone are concentric.

14 . A method as in claim 1 , further comprising adjusting a position of an insulative sheath in relation to the energy delivery body so as to affect a quantity of energy deliverable from the energy delivery body.

15 . A method as in claim 1 , further comprising delivering an agent to at least some of the target tissue cells.

16 . A method as in claim 15 , wherein the agent comprises a gene, a plasmid, a protein, a conditioning solution, a drug, a drug-eluting particle, a nanoparticle, a bioactive compound, an antimicrobial, a chemotherapy agent, an immunotherapy agent, a cytokine, a micelle, a liposome, an embolic, calcium, an antibiotic, a toxin, a cell or a combination of any of these.

17 . A method as in claim 1 , wherein treating the first portion comprises providing radiotherapy, microwave energy, high-intensity focused ultrasound energy or cryotherapy.

18 . A method as in claim 1 , wherein treating the first portion comprises delivery of energy to cause thermal ablation; or energy to cause cryotherapy.

19 . A method as in claim 1 , wherein treating the first portion comprises surgically removing the first portion.

20 . A method as in claim 1 , wherein the step of delivering pulsed electric field energy is timed in relation to the step of treating the first portion of the target tissue cells so that the step of delivering pulsed electric field energy functions as a neoadjuvant or adjuvant therapy to the first portion.

21 . A method as in claim 1 , wherein delivering the pulsed electric field energy comprises delivering the pulsed electric field energy so as to synergistically increase the effect of treating the first portion.

22 . A method as in claim 1 , wherein delivering the pulsed electric field energy comprises delivering the pulsed electric field energy in a manner which causes an abscopal effect by the patient.

23 . A method as in claim 1 , further comprising positioning a return electrode on the patient and wherein delivering the pulsed electric field energy comprises delivering the pulsed electric field energy in a monopolar fashion by utilizing the return electrode.

24 . A method as in claim 1 , wherein the target tissue cells comprise a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue.

25 . A method as in claim 1 , wherein the luminal structure comprises a blood vessel, an esophagus, a stomach, a pancreatic duct, a biliary duct, a small intestine, a large intestine, a colon, a rectum, a bladder, a urethra, a urinary collecting duct, a uterus, a vagina, a fallopian tube, a ureter, a renal tubule, a spinal canal, a spinal cord, an airway, a nasal cavity, a mouth, a heart chamber, a heart lumen, a kidney lumen, and or an organ lumen.

26 . A method as in claim 1 , wherein the luminal structure comprises an airway and the target tissue cells comprise a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue.

Assignments (3)
SECURITY INTEREST Recorded Jan 13, 2025
From: GALVANIZE THERAPEUTICS, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC
Reel/Frame 069879/0694 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2022
From: GLEIMAN, SETH S.; MERCER, NICHOLAS S.; O'BRIEN, TIMOTHY J.; WALDSTREICHER, JONATHAN R.; TAYLOR, KEVIN J.; MANGUAL-ARBELO, LUIS L.; NEAL, ROBERT E., II; KRIMSKY, WILLIAM SANFORD; CASTELLVI, QUIM
To: GALARY, INC.
Reel/Frame 061894/0547 →
CHANGE OF NAME Recorded Nov 28, 2022
From: GALARY, INC.
To: GALVANIZE THERAPEUTICS, INC.
Reel/Frame 061895/0387 →
Continuity (3)
Continuation PCTUS2020028844 · Apr 17, 2020
Provisional Application 62835846 · Apr 18, 2019
Related Publication 20220104875A1 · Apr 7, 2022
References Cited (365)
US 5386837A · Sterzer · 1995 [cited by applicant]
US 5906609A · Assa et al. · 1999 [cited by applicant]
US 6038478A · Yuen et al. · 2000 [cited by applicant]
US 6107699A · Swanson · 2000 [cited by applicant]
US 6233482B1 · Hofmann et al. · 2001 [cited by applicant]
US 6248056B1 · Persson · 2001 [cited by applicant]
US 6326177B1 · Schoenbach et al. · 2001 [cited by applicant]
US 6366808B1 · Schroeppel et al. · 2002 [cited by applicant]
US 6569149B2 · Dev et al. · 2003 [cited by applicant]
US 6733485B1 · Whitehurst et al. · 2004 [cited by applicant]
US 6738663B2 · Schroeppel et al. · 2004 [cited by applicant]
US 6994706B2 · Chornenky et al. · 2006 [cited by applicant]
US 7130697B2 · Chornenky et al. · 2006 [cited by applicant]
US 7395112B2 · Keisari et al. · 2008 [cited by applicant]
US 7412284B2 · Hofmann · 2008 [cited by applicant]
US 7412285B2 · Schroeppel et al. · 2008 [cited by applicant]
US 7565205B2 · Palti · 2009 [cited by applicant]
US 7565206B2 · Palti · 2009 [cited by applicant]
US 7599745B2 · Palti · 2009 [cited by applicant]
US 7599746B2 · Palti · 2009 [cited by applicant]
US 7713740B2 · Jaroszeski et al. · 2010 [cited by applicant]
US 7742811B2 · Schroeppel et al. · 2010 [cited by applicant]
US 7765010B2 · Chornenky et al. · 2010 [cited by applicant]
US 7805201B2 · Palti · 2010 [cited by applicant]
US RE42016E · Chornenky et al. · 2010 [cited by applicant]
US 7879610B1 · Heller et al. · 2011 [cited by applicant]
US 7917227B2 · Palti · 2011 [cited by applicant]
US 8014854B2 · Schroeppel et al. · 2011 [cited by applicant]
US 8019414B2 · Palti · 2011 [cited by applicant]
US 8024048B2 · Schroeppel et al. · 2011 [cited by applicant]
US 8026223B1 · Heller et al. · 2011 [cited by applicant]
US 8105324B2 · Palanker et al. · 2012 [cited by applicant]
US 8109926B2 · Azure · 2012 [cited by applicant]
US 8114070B2 · Rubinsky et al. · 2012 [cited by applicant]
US 8231603B2 · Hobbs et al. · 2012 [cited by applicant]
US 8244345B2 · Palti · 2012 [cited by applicant]
US 8298222B2 · Rubinsky et al. · 2012 [cited by applicant]
US 8406870B2 · Palti · 2013 [cited by applicant]
US 8465484B2 · Davalos et al. · 2013 [cited by applicant]
US 8500713B2 · Ferek-Petric · 2013 [cited by applicant]
US 8512334B2 · Nuccitelli et al. · 2013 [cited by applicant]
US 8600494B2 · Schroeppel et al. · 2013 [cited by applicant]
US 8634929B2 · Chornenky et al. · 2014 [cited by applicant]
US 8802643B1 · Heller et al. · 2014 [cited by applicant]
US 8814860B2 · Davalos et al. · 2014 [cited by applicant]
US 8927518B1 · Heller et al. · 2015 [cited by applicant]
US 8992517B2 · Davalos et al. · 2015 [cited by applicant]
US 9037230B2 · Goldfarb et al. · 2015 [cited by applicant]
US 9101764B2 · Nuccitelli et al. · 2015 [cited by applicant]
US 9125666B2 · Steinke et al. · 2015 [cited by applicant]
US 9168373B2 · Nuccitelli et al. · 2015 [cited by applicant]
US 9211155B2 · Fruland et al. · 2015 [cited by applicant]
US 9242041B2 · Kosik et al. · 2016 [cited by applicant]
US 9610364B1 · Heller et al. · 2017 [cited by applicant]
US 9629912B2 · Soikum et al. · 2017 [cited by applicant]
US 9655669B2 · Palti et al. · 2017 [cited by applicant]
US 9656066B2 · Nuccitelli et al. · 2017 [cited by applicant]
US 9724155B2 · Nuccitelli et al. · 2017 [cited by applicant]
US 9833617B2 · Travers et al. · 2017 [cited by applicant]
US 9943684B2 · Nuccitelli et al. · 2018 [cited by applicant]
US 10143512B2 · Rubinsky et al. · 2018 [cited by applicant]
US 10143759B1 · Heller et al. · 2018 [cited by applicant]
US 10154869B2 · Onik et al. · 2018 [cited by applicant]
US 10154874B2 · Davalos et al. · 2018 [cited by applicant]
US 10292755B2 · Arena et al. · 2019 [cited by applicant]
US 10391125B2 · Nuccitelli et al. · 2019 [cited by applicant]
US 10426847B2 · Pierce et al. · 2019 [cited by applicant]
US 10448989B2 · Arena et al. · 2019 [cited by applicant]
US 10471254B2 · Sano et al. · 2019 [cited by applicant]
US 10702337B2 · Waldstreicher et al. · 2020 [cited by applicant]
US 10939958B2 · Waldstreicher et al. · 2021 [cited by applicant]
US 11324543B2 · Waldstreicher et al. · 2022 [cited by applicant]
US 11369433B2 · Waldstreicher et al. · 2022 [cited by applicant]
US 11471208B2 · Waldstreicher et al. · 2022 [cited by applicant]
US 11547851B2 · Krimsky et al. · 2023 [cited by applicant]
US 11938317B2 · Krimsky et al. · 2024 [cited by applicant]
US 20010008016A1 · Kotani et al. · 2001 [cited by applicant]
US 20010020166A1 · Daly et al. · 2001 [cited by applicant]
US 20020010491A1 · Schoenbach et al. · 2002 [cited by applicant]
US 20020022839A1 · Stewart et al. · 2002 [cited by applicant]
US 20020103483A1 · Edwards · 2002 [cited by applicant]
US 20020115991A1 · Edwards · 2002 [cited by applicant]
US 20020198567A1 · Keisari et al. · 2002 [cited by applicant]
US 20030170898A1 · Gundersen et al. · 2003 [cited by applicant]
US 20030199050A1 · Mangano et al. · 2003 [cited by applicant]
US 20040044338A1 · Lennox et al. · 2004 [cited by applicant]
US 20050096647A1 · Steinke et al. · 2005 [cited by applicant]
US 20050171574A1 · Rubinsky et al. · 2005 [cited by applicant]
US 20050222646A1 · Kroll et al. · 2005 [cited by applicant]
US 20060264752A1 · Rubinsky et al. · 2006 [cited by applicant]
US 20060269531A1 · Beebe et al. · 2006 [cited by applicant]
US 20060293731A1 · Rubinsky et al. · 2006 [cited by applicant]
US 20070021803A1 · Deem · 2007 [cited by examiner]
US 20070025919A1 · Deem et al. · 2007 [cited by applicant]
US 20070129720A1 · Demarais et al. · 2007 [cited by applicant]
US 20070191904A1 · Libbus et al. · 2007 [cited by applicant]
US 20080015571A1 · Rubinsky et al. · 2008 [cited by applicant]
US 20080306570A1 · Rezai et al. · 2008 [cited by applicant]
US 20080319372A1 · Palti et al. · 2008 [cited by applicant]
US 20090247933A1 · Maor et al. · 2009 [cited by applicant]
US 20090281477A1 · Mikus et al. · 2009 [cited by applicant]
US 20090292342A1 · Rubinsky et al. · 2009 [cited by applicant]
US 20090306644A1 · Mayse et al. · 2009 [cited by applicant]
US 20100179530A1 · Long et al. · 2010 [cited by applicant]
US 20100228248A1 · Griffin · 2010 [cited by applicant]
US 20100240995A1 · Nuccitelli et al. · 2010 [cited by applicant]
US 20100256630A1 · Hamilton, Jr. et al. · 2010 [cited by applicant]
US 20110118732A1 · Rubinsky et al. · 2011 [cited by applicant]
US 20110152855A1 · Mayse et al. · 2011 [cited by applicant]
US 20110202052A1 · Gelbart et al. · 2011 [cited by applicant]
US 20110288545A1 · Beebe et al. · 2011 [cited by applicant]
US 20120143120A1 · Goldfarb et al. · 2012 [cited by applicant]
US 20120150172A1 · Ortiz · 2012 [cited by examiner]
US 20120220998A1 · Long et al. · 2012 [cited by applicant]
US 20120220999A1 · Long · 2012 [cited by applicant]
US 20120226271A1 · Callas et al. · 2012 [cited by applicant]
US 20120315704A1 · Beebe et al. · 2012 [cited by applicant]
US 20120330306A1 · Long et al. · 2012 [cited by applicant]
US 20140039491A1 · Bakos · 2014 [cited by examiner]
US 20140058294A1 · Gross · 2014 [cited by examiner]
US 20140081263A1 · Mesallum · 2014 [cited by applicant]
US 20140107478A1 · Seward et al. · 2014 [cited by applicant]
US 20150045788A1 · Litscher et al. · 2015 [cited by applicant]
US 20150119879A1 · Jameson et al. · 2015 [cited by applicant]
US 20150150618A1 · Onik et al. · 2015 [cited by applicant]
US 20150182282A1 · Zemel · 2015 [cited by examiner]
US 20150201996A1 · Rubinsky et al. · 2015 [cited by applicant]
US 20150258352A1 · Lin et al. · 2015 [cited by applicant]
US 20150289923A1 · Davalos et al. · 2015 [cited by applicant]
US 20150342669A1 · Flanagan et al. · 2015 [cited by applicant]
US 20160000499A1 · Lennox et al. · 2016 [cited by applicant]
US 20160128767A1 · Azamian et al. · 2016 [cited by applicant]
US 20160166310A1 · Stewart et al. · 2016 [cited by applicant]
US 20160199131A1 · Allison et al. · 2016 [cited by applicant]
US 20160206370A1 · Fruland et al. · 2016 [cited by applicant]
US 20160361109A1 · Weaver et al. · 2016 [cited by applicant]
US 20160367310A1 · Onik et al. · 2016 [cited by applicant]
US 20170049513A1 · Cosman, Jr. et al. · 2017 [cited by applicant]
US 20170065343A1 · Mickelsen · 2017 [cited by examiner]
US 20170087224A1 · Quake · 2017 [cited by applicant]
US 20170105793A1 · Cao et al. · 2017 [cited by applicant]
US 20170119465A1 · Long et al. · 2017 [cited by applicant]
US 20170135723A1 · Zarembinski · 2017 [cited by applicant]
US 20170215939A1 · Palti et al. · 2017 [cited by applicant]
US 20170216585A1 · Goldfarb et al. · 2017 [cited by applicant]
US 20170266283A1 · Soikum et al. · 2017 [cited by applicant]
US 20170266438A1 · Sano · 2017 [cited by examiner]
US 20170281934A1 · Giladi et al. · 2017 [cited by applicant]
US 20170304002A1 · Beebe et al. · 2017 [cited by applicant]
US 20170319843A1 · Beebe et al. · 2017 [cited by applicant]
US 20180000895A1 · Pierce et al. · 2018 [cited by applicant]
US 20180028267A1 · Onik et al. · 2018 [cited by applicant]
US 20180071014A1 · Neal · 2018 [cited by examiner]
US 20180085575A1 · Travers et al. · 2018 [cited by applicant]
US 20180104486A1 · Yoon et al. · 2018 [cited by applicant]
US 20180110557A1 · Muratori et al. · 2018 [cited by applicant]
US 20180110978A1 · Beebe et al. · 2018 [cited by applicant]
US 20180132922A1 · Neal, II · 2018 [cited by applicant]
US 20180154142A1 · Guo et al. · 2018 [cited by applicant]
US 20180193082A1 · Rubinsky et al. · 2018 [cited by applicant]
US 20180193088A1 · Sutton et al. · 2018 [cited by applicant]
US 20180200510A1 · Nuccitelli et al. · 2018 [cited by applicant]
US 20180221078A1 · Howard et al. · 2018 [cited by applicant]
US 20180263685A1 · Onik et al. · 2018 [cited by applicant]
US 20180289954A1 · Hebb et al. · 2018 [cited by applicant]
US 20180344378A1 · Wolf et al. · 2018 [cited by applicant]
US 20190038895A1 · Pianca et al. · 2019 [cited by applicant]
US 20190046791A1 · Ebbers et al. · 2019 [cited by applicant]
US 20190099214A1 · Rubinsky et al. · 2019 [cited by applicant]
US 20190105408A1 · Heller et al. · 2019 [cited by applicant]
US 20190117963A1 · Travers et al. · 2019 [cited by applicant]
US 20190117969A1 · Schmidt et al. · 2019 [cited by applicant]
US 20190160283A1 · Nuccitelli et al. · 2019 [cited by applicant]
US 20190223938A1 · Arena et al. · 2019 [cited by applicant]
US 20190223943A1 · Forsyth · 2019 [cited by examiner]
US 20190232048A1 · Latouche et al. · 2019 [cited by applicant]
US 20190239949A1 · Nuccitelli et al. · 2019 [cited by applicant]
US 20190254735A1 · Stewart · 2019 [cited by examiner]
US 20190269912A1 · Viswanathan et al. · 2019 [cited by applicant]
US 20190282294A1 · Davalos et al. · 2019 [cited by applicant]
US 20190299019A1 · Chornenky et al. · 2019 [cited by applicant]
US 20190307781A1 · Krex et al. · 2019 [cited by applicant]
US 20190328445A1 · Sano et al. · 2019 [cited by applicant]
US 20190350971A1 · Nuccitelli et al. · 2019 [cited by applicant]
US 20190351224A1 · Sano et al. · 2019 [cited by applicant]
US 20200000938A1 · Pierce et al. · 2020 [cited by applicant]
US 20200009377A1 · Chang et al. · 2020 [cited by applicant]
US 20200016067A1 · Gotlib et al. · 2020 [cited by applicant]
US 20200038093A1 · Onik · 2020 [cited by applicant]
US 20200046423A1 · Viswanathan et al. · 2020 [cited by applicant]
US 20200046967A1 · Ivey et al. · 2020 [cited by applicant]
US 20200275973A1 · O'Brien · 2020 [cited by examiner]
US 20210023362A1 · Lorenzo et al. · 2021 [cited by applicant]
US 20210146126A1 · Waldstreicher et al. · 2021 [cited by applicant]
US 20210236815A1 · Waldstreicher et al. · 2021 [cited by applicant]
US 20210236816A1 · Waldstreicher et al. · 2021 [cited by applicant]
US 20210393327A1 · Eyster et al. · 2021 [cited by applicant]
US 20220161027A1 · Aycock et al. · 2022 [cited by applicant]
US 20220387095A1 · Neal et al. · 2022 [cited by applicant]
US 20230149706A1 · Krimsky et al. · 2023 [cited by applicant]
US 20230172650A1 · Castellvi et al. · 2023 [cited by applicant]
US 20230248414A1 · Sano et al. · 2023 [cited by applicant]
CN 1867299A · 2006 [cited by applicant]
CN 101426551A · 2009 [cited by applicant]
CN 101553180A · 2009 [cited by applicant]
CN 102014779A · 2011 [cited by applicant]
CN 102725021A · 2012 [cited by applicant]
CN 103027745A · 2013 [cited by applicant]
CN 103252016A · 2013 [cited by applicant]
CN 103281978A · 2013 [cited by applicant]
CN 103781433A · 2014 [cited by applicant]
CN 103796603A · 2014 [cited by applicant]
CN 104602754A · 2015 [cited by applicant]
CN 104703557A · 2015 [cited by applicant]
CN 107194119A · 2017 [cited by applicant]
CN 107205772A · 2017 [cited by applicant]
CN 107921258A · 2018 [cited by applicant]
CN 108024803A · 2018 [cited by applicant]
CN 108778172A · 2018 [cited by applicant]
CN 109788979A · 2019 [cited by applicant]
EP 0935482B1 · 2005 [cited by applicant]
EP 1991303A2 · 2008 [cited by applicant]
EP 1648555B1 · 2015 [cited by applicant]
EP 2957248A1 · 2015 [cited by applicant]
EP 2736432B1 · 2016 [cited by applicant]
EP 2661236B1 · 2016 [cited by applicant]
EP 3003470B1 · 2017 [cited by applicant]
EP 3290082A2 · 2018 [cited by applicant]
EP 2994045B1 · 2019 [cited by applicant]
EP 3569144A1 · 2019 [cited by applicant]
JP 2003529401A · 2003 [cited by applicant]
JP 2007504910A · 2007 [cited by applicant]
JP 2010509032A · 2010 [cited by applicant]
JP 2012515018A · 2012 [cited by applicant]
JP 2017518805A · 2017 [cited by applicant]
WO WO9814238A1 · 1998 [cited by applicant]
WO WO9906101A1 · 1999 [cited by applicant]
WO WO0110319A1 · 2001 [cited by applicant]
WO WO02098501A2 · 2002 [cited by applicant]
WO WO03047684A2 · 2003 [cited by applicant]
WO WO2004037341A2 · 2004 [cited by applicant]
WO WO2004110371A2 · 2004 [cited by applicant]
WO WO2005044371A1 · 2005 [cited by applicant]
WO WO2005065284A2 · 2005 [cited by applicant]
WO WO2005115535A2 · 2005 [cited by applicant]
WO WO2005032646A3 · 2006 [cited by applicant]
WO WO2006036706A1 · 2006 [cited by applicant]
WO WO2006085150A2 · 2006 [cited by applicant]
WO WO2006116608A2 · 2006 [cited by applicant]
WO WO2006131816A2 · 2006 [cited by applicant]
WO WO2007001747A2 · 2007 [cited by applicant]
WO WO2007001751A1 · 2007 [cited by applicant]
WO WO2007039799A3 · 2007 [cited by applicant]
WO WO2007100727A2 · 2007 [cited by applicant]
WO WO2007103070A2 · 2007 [cited by applicant]
WO WO2008034100A2 · 2008 [cited by applicant]
WO WO2008087489A2 · 2008 [cited by applicant]
WO WO2009137800A2 · 2009 [cited by applicant]
WO WO2010022275A1 · 2010 [cited by applicant]
WO WO2010093692A2 · 2010 [cited by applicant]
WO WO2010107947A1 · 2010 [cited by applicant]
WO WO2010118387A1 · 2010 [cited by applicant]
WO WO2010151277A1 · 2010 [cited by applicant]
WO WO2011135294A1 · 2011 [cited by applicant]
WO WO2012088149A2 · 2012 [cited by applicant]
WO WO2012118659A1 · 2012 [cited by applicant]
WO WO2014181167A1 · 2014 [cited by applicant]
WO WO2014197240A2 · 2014 [cited by applicant]
WO WO2014204978A1 · 2014 [cited by applicant]
WO WO2015085162A1 · 2015 [cited by applicant]
WO WO2015175570A1 · 2015 [cited by applicant]
WO WO2015192027A1 · 2015 [cited by applicant]
WO WO2016014264A1 · 2016 [cited by applicant]
WO WO2016036891A1 · 2016 [cited by applicant]
WO WO2016060983A1 · 2016 [cited by applicant]
WO WO2016089781A1 · 2016 [cited by applicant]
WO WO2016112359A1 · 2016 [cited by applicant]
WO WO2016123608A2 · 2016 [cited by applicant]
WO WO2016126778A1 · 2016 [cited by applicant]
WO WO2016149575A1 · 2016 [cited by applicant]
WO WO2016154473A1 · 2016 [cited by applicant]
WO WO2016178697A1 · 2016 [cited by applicant]
WO WO2016179712A1 · 2016 [cited by applicant]
WO WO2016201264A1 · 2016 [cited by applicant]
WO WO2017024123A1 · 2017 [cited by applicant]
WO WO2017120169A1 · 2017 [cited by applicant]
WO WO2017173089A1 · 2017 [cited by applicant]
WO WO2017175116A1 · 2017 [cited by applicant]
WO WO2018005511A1 · 2018 [cited by applicant]
WO WO2018010659A1 · 2018 [cited by applicant]
WO WO2018065806A1 · 2018 [cited by applicant]
WO WO2018067999A1 · 2018 [cited by applicant]
WO WO2018075946A1 · 2018 [cited by applicant]
WO WO2018106672A1 · 2018 [cited by applicant]
WO WO2019032474A1 · 2019 [cited by applicant]
WO WO2019084011A1 · 2019 [cited by applicant]
WO WO2019095604A1 · 2019 [cited by applicant]
WO WO2019100016A1 · 2019 [cited by applicant]
WO WO2019108540A1 · 2019 [cited by applicant]
WO WO2019133606A1 · 2019 [cited by applicant]
WO WO2019133608A1 · 2019 [cited by applicant]
WO WO2019178500A1 · 2019 [cited by applicant]
WO WO2019197973A1 · 2019 [cited by applicant]
WO WO2020010188A1 · 2020 [cited by applicant]
WO WO2020018662A1 · 2020 [cited by applicant]
WO WO2020215007A1 · 2020 [cited by applicant]
WO WO2021011733 · 2021 [cited by applicant]
WO WO2021127558A1 · 2021 [cited by applicant]
WO WO2021207385A1 · 2021 [cited by applicant]
WO WO2022031797A1 · 2022 [cited by applicant]
WO WO2022204479A1 · 2022 [cited by applicant]
WO WO2022260723A1 · 2022 [cited by applicant]
Appelbaum et al., US Findings after Irreversible Electroporation Ablation: Radiologic-Pathologic Correlation, Radiology: vol. 262: No. 1—Jan. 2012. [cited by applicant]
Arschang Valipour et al. [cited by applicant]
Charalambous et al., The Efficacy and Safety of the Open Approach Irreversible Electroporation in the Treatment of Pancreatic Cancer: A Systematic Review, European Journal of Surgical Oncology; vol. 46, No. 9, Sep. 2020. [cited by applicant]
Davalos et al., Implications and Considerations of Thermal Effects When Applying Irreversible Electroporation Tissue Ablation Therapy, Prostate; vol. 75, No. 10; pp. 1114-1118, Jul. 1, 2015. [cited by applicant]
Edd et al., In Vivo Results of a New Focal Tissue Ablation Technique: Irreversible Electroporation, IEEE Transactions On Biomedical Engineering, vol. 53, No. 5; pp. 1409-1415; Jun. 2006. [cited by applicant]
Frandsen et al., Calcium electroporation Q4 in three cell lines; a comparison of bleomycin 2 and calcium, calcium compounds, and pulsing conditions, Biochimica et Biophysica Acta, vol. 1840, No. 3; pp. 1204-1208, Mar. 2… [cited by applicant]
International Search Report and Written Opinion for PCT/US2020/028844 on Sep. 4, 2020. [cited by applicant]
Kundalia et al., Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation e Results from the MACPIE-I study, European Journal of Surgical Oncology, vol. 47, No. 10: pp. 2571-2578; Oct. 202… [cited by applicant]
Maor et al., Irreversible Electroporation Attenuates Neointimal Formation After Angioplasty, IEEE Transactions on Biomedical Engineering, vol. 55, No. 9, Sep. 2008. [cited by applicant]
Maor et al., The Effect of Irreversible Electroporation on Blood Vessels, Technology in Cancer Research and Treatment, vol. 6, No. 4, Aug. 2007. [cited by applicant]
Reddy et al., Pulsed Field Ablation of Paroxysmal Atrial Fibrillation, JACC Clin Electrophysiology vol. 7 No. 5, pp. 614-627, May 2021. [cited by applicant]
Rubinsky et al., “Irreversible Electroporation: a New Ablation Modality—Clinical Implications,” Tech. Cancer Res. Treatment 6:1-12 (2007). [cited by applicant]
Timmer et al., Irreversible Electroporation for Locally Advanced Pancreatic Cancer, Techniques in Vascular and Interventional Radiology vol. 23, Issue 2, Jun. 2020. [cited by applicant]
Verma et al., Primer on Pulsed Electrical Field Ablation: Understanding the Benefits and Limitations, Circulation: Arrhythmia and Electrophysiology, vol. 14, No. 9, Sep. 20, 2021. [cited by applicant]
Xie et al., Ablation of Myocardial Tissue With Nano second Pulsed Electric Fields, PLOS ONE, vol. 10, No. 12, Dec. 14, 2015. [cited by applicant]
Yavin et al., Pulsed Field Ablation Using a Lattice Electrode for Focal Energy Delivery, Circulation: Arrhythmia and Electrophysiology, vol. 13, No. 6, May 6, 2020. [cited by applicant]
A. Valipour et al. Bronchial Rheoplasty Treatment for Chronic Bronchitis Using the Rheox System, 2020 American Thoracic Society, Abstract, Aug. 5, 2020. [cited by applicant]
A. Valipour, et al. [cited by applicant]
Arschang Valipour et al. Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial, American Journal of Respiratory and Critical Care Medicine, vol. 202, Issue 5, 2… [cited by applicant]
Arschang Valipour, et al. Late Breaking Abstract—Bronchial Rheoplasty for Treatment of Chronic Bronchitis: 6 Month Results from a Prospective Multi-Center Study, Abstract, European Respiratory Journal 2019, pp. 1-5. [cited by applicant]
Co-pending U.S. Appl. No. 17/941,815, inventors Waldstreicher; Jonathan Reuben et al., filed on Sep. 9, 2022. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2018/067501 dated Jun. 30, 2020. [cited by applicant]
Pallav L Shah, et al. [cited by applicant]
PCT/US2018/067501 International Search Report and Written Opinion dated Mar. 13, 2019. [cited by applicant]
S. Fernandez-Bussy, et al. [cited by applicant]
U.S. Appl. No. 16/914,072 Notice of Allowance dated Jun. 20, 2022. [cited by applicant]
U.S. Appl. No. 17/214,688 Notice of Allowance dated Feb. 4, 2022. [cited by applicant]
U.S. Appl. No. 17/214,688 Notice of Allowance dated Mar. 2, 2022. [cited by applicant]
U.S. Appl. No. 17/214,688 Office Action dated Sep. 7, 2021. [cited by applicant]
U.S. Appl. No. 17/214,688 Office Action dated May 25, 2021. [cited by applicant]
U.S. Appl. No. 16/914,072 Office Action dated Nov. 26, 2021. [cited by applicant]
V. Kim et al. [cited by applicant]
Valipour, A., Ing, A., Williamson, J., et al. [cited by applicant]
EP18836576.1 Search Report dated Jun. 8, 2021. [cited by applicant]
EP20792123.0 Extended and Supplementary European Search Report dated Dec. 21, 2022. [cited by applicant]
EP23178276.4 Extended European Search Report dated Jun. 26, 2023. [cited by applicant]
International Search Report and Written Opinion for PCT/US2018/067504 on Jun. 30, 2020. [cited by applicant]
Lu, et al., “Sequence-Modified Antibiotic Resistance Genes Provide Sustained Plasmid- Mediated Transgene Expression in Mammals” (2017) Molecular Therapy, vol. 25, No. 5, pp. 1187-1198. [cited by applicant]
PCT/US2021/026221 International Search Report and Written Opinion dated Jul. 21, 2021. [cited by applicant]
PCT/US2022/015217 International Search Report and Written Opinion dated May 6, 2022. [cited by applicant]
PCT/US2022/021888 International Search Report and Written Opinion dated Jun. 16, 2022. [cited by applicant]
U.S. Appl. No. 16/914,200 Notice of Allowance dated Sep. 8, 2022. [cited by applicant]
U.S. Appl. No. 16/914,200 Office Action dated May 4, 2022. [cited by applicant]
U.S. Appl. No. 16/914,200 Office Action dated Oct. 22, 2021. [cited by applicant]
U.S. Appl. No. 18/077,097 Office Action dated Aug. 3, 2023. [cited by applicant]
Co-pending U.S. Appl. No. 18/472,535, inventors Castellvi; Quim et al., filed Sep. 22, 2023. [cited by applicant]
U.S. Appl. No. 18/077,097 Notice of Allowance dated Oct. 27, 2023. [cited by applicant]
Co-pending U.S. Appl. No. 18/416,505, inventor Neal; Robert E., filed Jan. 18, 2024. [cited by applicant]
Co-pending U.S. Appl. No. 18/423,043, inventor Krimsky; William Sanford, filed Jan. 25, 2024. [cited by applicant]
EP21785398.5 Extended European Search Report dated Apr. 4, 2024. [cited by applicant]
U.S. Appl. No. 18/077,097 Corrected Notice of Allowability dated Dec. 26, 2023. [cited by applicant]
U.S. Appl. No. 18/416,505 Office Action dated Oct. 1, 2024. [cited by applicant]
U.S. Appl. No. 18/423,043 Office Action dated Nov. 4, 2024. [cited by applicant]